Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis
(WorldNews Switzerland)

Basel, 21 July 2017 Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis If approved, Actemra/RoActemra would be the first therapy for the treatment of giant cell arteritis (GCA) in Europe GCA can lead to blindness, aortic aneurysm or stroke if left untreated The positive opinion is based on the outcome of the phase III GiACTA study Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Actemra®/RoActemra® (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition. Based on this...